Clinical experience with 19.552 R.P. in Nordic countries.
D000293:Adolescent; D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010169:Palmitic Acids / Q000627:therapeutic use; D010259:Paranoid Disorders / Q000188:drug therapy; D010640:Phenothiazines; D010880:Piperidines / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010169:Palmitic Acids; D010640:Phenothiazines; D010880:Piperidines; D013449:Sulfonamides; D014149:Tranquilizing Agents